You are here: Industry Insights > HTX-011

News List

Heron Announces Successful FDA Meeting for Postoperative Pain Treatment americanpharmaceuticalreview
September 23, 2020
Heron Therapeutics announced a successful Type A meeting with the U.S. Food and Drug Administration (FDA) in which alignment was reached on the plans for the Company to resubmit the New Drug Application (NDA) for HTX-011 for the management of p...
Heron Receives CRL for HTX-011 for Postoperative Pain americanpharmaceuticalreview
July 08, 2020
Heron Therapeutics has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for HTX-011 for the management of postoperative pain.
Heron Receives FDA Extension of NDA Review Period for Postoperative Pain Treatment americanpharmaceuticalreview
March 09, 2020
Heron Therapeutics announced the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for HTX-011 by up to three months.
FDA Grants Priority Review Designation for HTX-011 americanpharmaceuticalreview
January 03, 2019
Heron Therapeutics announced the U.S. Food and Drug Administration (FDA) has accepted the new drug application (NDA) for Heron's investigational agent, HTX-011, and has granted it a Priority Review designation.....
HTX-011 for Postoperative Pain Management Receives Breakthrough Therapy Designation from FDA americanpharmaceuticalreview
June 27, 2018
Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs